Tag Archives: cisplatin/pemetrexed

New Mesothelioma Drug Granted Special FDA Status

The Federal Drug Administration (FDA) has granted orphan drug status to a medication that may help boost the effectiveness of the standard cisplatin/pemetrexed chemotherapy combination for mesothelioma. CBP501, produced by the Japanese Drug company CanBas, is a novel synthetic peptide that seems to enhance the effectiveness of cisplatin by acting on multiple pathways that govern the lifecycle of cells and the natural repair of DNA damage. By modulating the production of a certain enzyme, it allows mesothelioma cells to become more susceptible to the damaging effects of platinum (cisplatin) build-up. At the same time, it prevents the cells from properly repairing themselves. The drug has also shown the ability to resensitize mesothelioma cells that have become resistant to cisplatin. The FDA’s … Continue reading New Mesothelioma Drug Granted Special FDA Status »